CYP3A5 mRNA degradation by nonsense-mediated mRNA decay

Molecular Pharmacology

Volumn 68, Issue 3, 2005, Pages 808-815

  Busi, Florent ^a,b   Cresteil, Thierry ^a  

^a CNRS   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CYCLOHEXIMIDE; CYTOCHROME P450 3A5; MESSENGER RNA; SMALL INTERFERING RNA; STEROID;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CODON; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INDUCTION; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MOLECULAR MODEL; MOLECULAR STABILITY; NEWBORN; PHENOTYPE; PRIORITY JOURNAL; RIBOSOME; RNA DEGRADATION; RNA SPLICING; STOP CODON; WILD TYPE;

ADULT; BASE SEQUENCE; CELL LINE, TUMOR; CODON, TERMINATOR; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HUMANS; HYDROLYSIS; INFANT, NEWBORN; POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 23944493394     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.014225     Document Type: Article

References (38)

1. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, and Wojnowski L (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279:38379-38385.
2. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890.
3. Cresteil T, Flinois JP, Pfister A, and Leroux JP (1979) Effect of microsomal preparations and induction on cytochrome P-450-dependent monooxygenases in fetal and neonatal rat liver. Biochem Pharmacol 28:2057-2063.
4. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, and Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392.
5. Domanski TL, Finta C, Halpert JR, and Zaphiropoulos PG (2001) cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 59:386-392.
6. Eichelbaum M and Burk O (2001) CYP3A Genetics in drug metabolism. Nat Med 7:285-287.
7. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (Lond) 411:494-498.
8. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, Matsumoto K, Maihara A, Momiyama K, Ito T, et al. (2004) CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 4:34-39.
9. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, et al. (2001) Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-121.
10. Harries LW, Hattersley AT, and Ellard S (2004) Messenger RNA transcripts of the hepatocyte nuclear factor-1alpha gene containing premature termination codons are subject to nonsense-mediated decay. Diabetes 53:500-504.
11. Hesselink DA, van Schaik RH, van der Heiden I, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
12. Holbrook JA, Neu-Yilik G, Hentze MW, and Kulozik AE (2004) Nonsense-mediated decay approaches the clinic. Nat Genet 36:801-808.
13. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
14. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
15. Jounaidi Y, Hyrailles V, Gervot L, and Maurel P (1996) Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221:466-470.
16. Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, Gordon EF, Polzin JE, Gustavson LE, Driscoll RM, et al. (2004) CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 75:516-528.
17. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
19. Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625-634.
20. Lamba JK, Adachi M, Sun D, Tammur J, Schuetz EG, Allikmets R, and Schuetz JD (2003) Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum Mol Genet 12:99-109.
21. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, and Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472.
22. Lei XD, Chapman B, and Hankinson O (2001) Loss of Cyp1a1 messenger RNA expression due to nonsense-mediated decay. Mol Pharmacol 60:388-393.
23. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
24. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, and Holt DW (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486-1489.
25. Mendell JT, ap Rhys CM, and Dietz HC (2002) Separable roles for Rent1/hUpf1 in altered splicing and decay of nonsense transcripts. Science (Wash DC) 298:419-422.
26. Oscarson M and Ingelman-Sundberg M (2002) CYPalleles: a web page for nomenclature of human cytochrome P450 alleles. Drug Metab Pharmacokinet 17:491-495.
27. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, Konings F, and Armstrong M (2000) Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415-424.
28. Rozen S and Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386.
29. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, et al. (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020.
30. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
31. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, and Zaya MJ (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573-582.
32. Sureau A, Gattoni R, Dooghe Y, Stevenin J, and Soret J (2001) SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs. EMBO (Eur Mol Biol Organ) J 20:1785-1796.
33. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
34. Wilusz CJ, Wormington M, and Peltz SW (2001) The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2:237-246.
35. Wojnowski L and Brockmoller J (2004) Single nucleotide polymorphism characterization by MRNA expression imbalance assessment. Pharmacogenetics 14:267-269.
36. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA, and Smith CW (2004) Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell 13:91-100.
37. Wrighton SA, Ring BJ, Watkins PB, and VandenBranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 36:97-105.
38. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.